Tvardi Therapeutics (TVRD) Competitors $26.20 +0.24 (+0.92%) As of 08/1/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesSEC FilingsTrendsBuy This Stock TVRD vs. AKBA, ORIC, VERV, IMNM, ZYME, PROK, LENZ, MLYS, TRVI, and MENSShould you be buying Tvardi Therapeutics stock or one of its competitors? The main competitors of Tvardi Therapeutics include Akebia Therapeutics (AKBA), Oric Pharmaceuticals (ORIC), Verve Therapeutics (VERV), Immunome (IMNM), Zymeworks (ZYME), ProKidney (PROK), LENZ Therapeutics (LENZ), Mineralys Therapeutics (MLYS), Trevi Therapeutics (TRVI), and Jyong Biotech (MENS). These companies are all part of the "pharmaceutical products" industry. Tvardi Therapeutics vs. Its Competitors Akebia Therapeutics Oric Pharmaceuticals Verve Therapeutics Immunome Zymeworks ProKidney LENZ Therapeutics Mineralys Therapeutics Trevi Therapeutics Jyong Biotech Akebia Therapeutics (NASDAQ:AKBA) and Tvardi Therapeutics (NASDAQ:TVRD) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, media sentiment, valuation, profitability and analyst recommendations. Does the media refer more to AKBA or TVRD? In the previous week, Akebia Therapeutics had 4 more articles in the media than Tvardi Therapeutics. MarketBeat recorded 4 mentions for Akebia Therapeutics and 0 mentions for Tvardi Therapeutics. Tvardi Therapeutics' average media sentiment score of 0.00 beat Akebia Therapeutics' score of -0.04 indicating that Tvardi Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Akebia Therapeutics Neutral Tvardi Therapeutics Neutral Is AKBA or TVRD more profitable? Akebia Therapeutics has a net margin of -24.51% compared to Tvardi Therapeutics' net margin of -595.39%. Akebia Therapeutics' return on equity of 0.00% beat Tvardi Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Akebia Therapeutics-24.51% N/A -18.92% Tvardi Therapeutics -595.39%-710.04%-79.00% Do analysts prefer AKBA or TVRD? Akebia Therapeutics currently has a consensus price target of $6.75, suggesting a potential upside of 81.45%. Tvardi Therapeutics has a consensus price target of $64.25, suggesting a potential upside of 145.23%. Given Tvardi Therapeutics' higher probable upside, analysts clearly believe Tvardi Therapeutics is more favorable than Akebia Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Akebia Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Tvardi Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals hold more shares of AKBA or TVRD? 33.9% of Akebia Therapeutics shares are owned by institutional investors. Comparatively, 44.7% of Tvardi Therapeutics shares are owned by institutional investors. 3.0% of Akebia Therapeutics shares are owned by company insiders. Comparatively, 3.1% of Tvardi Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has preferable earnings and valuation, AKBA or TVRD? Akebia Therapeutics has higher revenue and earnings than Tvardi Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAkebia Therapeutics$160.18M6.10-$69.41M-$0.21-17.71Tvardi Therapeutics$7.14M34.35-$70.87MN/AN/A Which has more risk and volatility, AKBA or TVRD? Akebia Therapeutics has a beta of 0.96, indicating that its stock price is 4% less volatile than the S&P 500. Comparatively, Tvardi Therapeutics has a beta of 0.21, indicating that its stock price is 79% less volatile than the S&P 500. SummaryAkebia Therapeutics beats Tvardi Therapeutics on 9 of the 14 factors compared between the two stocks. Get Tvardi Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TVRD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TVRD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TVRD vs. The Competition Export to ExcelMetricTvardi TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$243.01M$3.00B$5.49B$9.54BDividend YieldN/A2.43%4.73%4.09%P/E RatioN/A17.7428.8323.83Price / Sales34.35179.21372.0766.02Price / CashN/A41.9535.4557.96Price / Book-8.688.508.275.54Net Income-$70.87M-$55.06M$3.25B$259.28M7 Day Performance-1.21%-3.99%-3.73%-4.68%1 Month Performance22.14%9.58%4.29%4.36%1 Year PerformanceN/A6.70%25.87%17.88% Tvardi Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TVRDTvardi TherapeuticsN/A$26.20+0.9%$64.25+145.2%N/A$243.01M$7.14M0.0080Positive NewsAKBAAkebia Therapeutics3.7129 of 5 stars$3.56-7.3%$6.75+89.6%+188.4%$1.01B$160.18M-16.95430News CoverageUpcoming EarningsHigh Trading VolumeORICOric Pharmaceuticals4.5559 of 5 stars$11.44-2.5%$18.57+62.3%-4.6%$999.68MN/A-6.1280News CoveragePositive NewsGap DownVERVVerve Therapeutics3.4873 of 5 stars$11.13flat$14.57+30.9%N/A$992.13M$32.33M-5.27110News CoverageIMNMImmunome1.9945 of 5 stars$10.87-3.3%$23.33+114.7%-29.7%$978.02M$10.94M-3.4240News CoveragePositive NewsGap DownZYMEZymeworks0.0318 of 5 stars$13.33-4.9%N/AN/A$976.27M$76.30M-8.95460PROKProKidney3.2945 of 5 stars$3.29+0.9%$6.25+90.0%+29.4%$954.19M$80K-5.483Upcoming EarningsGap DownLENZLENZ Therapeutics1.6846 of 5 stars$31.62-5.3%$46.60+47.4%+21.7%$940.08MN/A-17.86110Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionMLYSMineralys Therapeutics2.5594 of 5 stars$14.32+0.4%$32.25+125.2%+13.4%$929.40MN/A-3.8428News CoverageInsider TradeTRVITrevi Therapeutics2.7757 of 5 stars$7.87+0.4%$20.88+165.2%+136.5%$919.58MN/A-17.4920News CoverageUpcoming EarningsShort Interest ↑MENSJyong BiotechN/A$13.80+17.1%N/AN/A$895.61MN/A0.0031Positive NewsQuiet Period Expiration Related Companies and Tools Related Companies Akebia Therapeutics Alternatives Oric Pharmaceuticals Alternatives Verve Therapeutics Alternatives Immunome Alternatives Zymeworks Alternatives ProKidney Alternatives LENZ Therapeutics Alternatives Mineralys Therapeutics Alternatives Trevi Therapeutics Alternatives Jyong Biotech Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TVRD) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tvardi Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tvardi Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
